Intended Use
This product is used for the qualitative in vitro detection of mumps virus IgG antibodies in human serum/plasma or whole blood samples.
Suitable for auxiliary diagnosis of mumps virus infection; mumps virus IgG antibody detection in vivo after vaccination with mumps component vaccine and mumps virus IgG antibody detection in normal or susceptible people.
Contents of Kit
1. Pre-coated plate: 12T×8, inactivated purified mumps virus antigen
2. Mouse anti-human IgG monoclonal antibody enzyme label: 10ml × 1 bottle, HRP enzyme-labeled mouse anti-human IgG monoclonal antibody, containing stabilizer and biological preservatives
3. Concentrated washing solution (20×): 30ml×1 bottle, 20 times concentrated phosphate buffer, containing NaCl, Tween-20
4. Sample diluent: 50ml×1 bottle, sodium citrate buffer, stabilizer, etc.
5. Negative control substance: 0.5ml×1 bottle, inactivated human anti-mumps virus IgG negative serum, stabilizer
6. Positive control substance: 0.5ml×1 bottle, inactivated human anti-mumps virus IgG positive serum, stabilizer
7. Substrate A: 5.0ml×1 bottle, the main component is carbamide peroxide
8. Substrate B: 5.0ml×1 bottle, the main component is TMB
9. Stop solution: 5.0ml×1 bottle, 0.5M H2SO4 solution
10. Ziplock bag: 1 serving
11. Parafilm: 3 sheets
Storage
1. Store refrigerated at 2-8°C and away from light. Freezing is prohibited. The validity period is 12 months.
2. Unused pre-coated boards should be immediately put into a ziplock bag with desiccant and sealed, and the storage time should not exceed one week in an environment of 2-8°C.
3. Any unused reagents of other components should be capped immediately and stored in an environment of 2-8°C. The storage time should not exceed one week.
4. Please refer to the product label for the production date and expiration date of the product.
General Description
Mumps virus belongs to the genus Paramyxovirus in the family Paramyxoviridae and has only one serotype. It can be divided into different genotypes based on sequence differences in genes encoding small hydrophobin proteins (SH genes). The virus is a single-stranded RNA virus, surrounded by a lipid membrane from the host cell. There are two components on the virus surface, hemagglutinin-neuraminidase protein and lytic protein, which play an important role in the virulence of the virus. Antibodies to the hemagglutinin-neuraminidase protein neutralize the virus, which can replicate in many cells, including chicken embryo cells.
The initial symptoms of mumps are generally non-specific, such as myalgia, headache, malaise, and low-grade fever. Typical unilateral or bilateral parotid gland swelling will appear within 1 day. In 10% of cases, symptoms of obvious involvement of other salivary glands can be seen. After about a week, the fever and swelling of the parotid gland subside, and unless complications occur, the disease usually resolves. About 30% of cases have only non-specific symptoms or no symptoms. Most infections in children under 2 years old are subclinical. They are contagious from 2 days before parotid gland enlargement to 9 days after parotid gland enlargement. There is no specific treatment. Although complications may occur, mumps is generally a mild, self-limiting disease with a mortality rate of only 1/10,000. 50% to 60% of patients may develop cerebrospinal fluid leukocytosis (>5/mm3), but no encephalitis/ Meningitis manifestations; up to 15% of patients have symptoms of meningitis. Mumps encephalitis occurs in 0.02% to 0.3% of cases. Although the mortality rate of mumps encephalitis is low, permanent sequelae can occur, such as paralysis, convulsions, cranial nerve paralysis, aqueductal stenosis, and cerebral edema. Acquired sensorineural deafness caused by mumps is one of the main causes of childhood deafness, occurring in approximately 5/100,000 mumps patients. About 20% of post-pubertal males suffering from mumps will develop orchitis, of which 20% may involve both sides. However, orchitis secondary to mumps rarely causes infertility. Symptomatic oophoritis and mastitis are rare and do not have permanent sequelae. Spontaneous miscarriage may occur in 25% of cases of mumps infection within 12 weeks of pregnancy. However, there have been no reports of fetal malformation if mumps virus infection occurs during pregnancy. Pancreatitis occurs in approximately 4% of cases, but the relationship between mumps-induced pancreatitis and diabetes is uncertain.
Life-long protection is generally obtained after natural infection, but recurrence of mumps has also been reported. IgA antibodies secreted by the nasopharyngeal mucosa have the effect of neutralizing the mumps virus and can be regarded as the first line of defense. Immunity to mumps is associated with serum-specific antibodies. It is unclear whether lifelong immunity must be achieved through natural boosting of the body's immune system by wild viruses circulating in the human population. Detection of serum-specific IgG antibodies using commonly used immunological methods can demonstrate the body's immunity.
At present, the main methods for detecting mumps virus-specific IgG antibodies include: neutralization test, hemagglutination inhibition test, enzyme-linked immunoassay (ELISA), etc.
COA
Publication 
Loading ......
